Literature DB >> 33575544

What next after GDP-based cost-effectiveness thresholds?

Y-Ling Chi1, Mark Blecher2, Kalipso Chalkidou1,3, Anthony Culyer4, Karl Claxton4, Ijeoma Edoka5, Amanda Glassman6, Noemi Kreif4, Iain Jones7, Andrew J Mirelman4, Mardiati Nadjib8, Alec Morton9, Ole Frithjof Norheim10, Jessica Ochalek4, Shankar Prinja11, Francis Ruiz1,3, Yot Teerawattananon12, Anna Vassall13, Alexander Winch3.   

Abstract

Public payers around the world are increasingly using cost-effectiveness thresholds (CETs) to assess the value-for-money of an intervention and make coverage decisions. However, there is still much confusion about the meaning and uses of the CET, how it should be calculated, and what constitutes an adequate evidence base for its formulation. One widely referenced and used threshold in the last decade has been the 1-3 GDP per capita, which is often attributed to the Commission on Macroeconomics and  WHO guidelines on Choosing Interventions that are Cost Effective (WHO-CHOICE). For many reasons, however, this threshold has been widely criticised; which has led experts across the world, including the WHO, to discourage its use. This has left a vacuum for policy-makers and technical staff at a time when countries are wanting to move towards Universal Health Coverage . This article seeks to address this gap by offering five practical options for decision-makers in low- and middle-income countries that can be used instead of the 1-3 GDP rule, to combine existing evidence with fair decision-rules or develop locally relevant CETs. It builds on existing literature as well as an engagement with a group of experts and decision-makers working in low, middle and high income countries. Copyright:
© 2020 Chi YL et al.

Entities:  

Keywords:  Cost-effectiveness thresholds; cost-effectiveness analysis; health opportunity cost; priority setting

Year:  2020        PMID: 33575544      PMCID: PMC7851575          DOI: 10.12688/gatesopenres.13201.1

Source DB:  PubMed          Journal:  Gates Open Res        ISSN: 2572-4754


  11 in total

1.  Xpert Ultra stool testing to diagnose tuberculosis in children in Ethiopia and Indonesia: a model-based cost-effectiveness analysis.

Authors:  Nyashadzaishe Mafirakureva; Eveline Klinkenberg; Ineke Spruijt; Jens Levy; Debebe Shaweno; Petra de Haas; Nastiti Kaswandani; Ahmed Bedru; Rina Triasih; Melaku Gebremichael; Peter J Dodd; Edine W Tiemersma
Journal:  BMJ Open       Date:  2022-07-01       Impact factor: 3.006

2.  Incremental cost and cost-effectiveness of the addition of indoor residual spraying with pirimiphos-methyl in sub-Saharan Africa versus standard malaria control: results of data collection and analysis in the Next Generation Indoor Residual Sprays (NgenIRS) project, an economic-evaluation.

Authors:  Joshua Yukich; Peder Digre; Sara Scates; Luc Boydens; Emmanuel Obi; Nicky Moran; Allison Belemvire; Mariandrea Chamorro; Benjamin Johns; Keziah L Malm; Lena Kolyada; Ignatius Williams; Samuel Asiedu; Seydou Fomba; Jules Mihigo; Desire Boko; Baltazar Candrinho; Rodaly Muthoni; Jimmy Opigo; Catherine Maiteki-Sebuguzi; Damian Rutazaana; Josephat Shililu; Asaph Muhanguzi; Kassahun Belay; Joel Kisubi; Joselyn Annet Atuhairwe; Presley Musonda; Nduka Iwuchukwu; John Ngosa; Elizabeth Chizema; Reuben Zulu; Emmanuel Kooma; John Miller; Adam Bennett; Kyra Arnett; Kenzie Tynuv; Christelle Gogue; Joseph Wagman; Jason H Richardson; Laurence Slutsker; Molly Robertson
Journal:  Malar J       Date:  2022-06-11       Impact factor: 3.469

3.  Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis.

Authors:  Pablo Manuel Bianculli; Lucile Bellier; Ignacio Olivera Mangado; Carlos Grau Pérez; Gustavo Mieres; Luis Lazarov; Audrey Petitjean; Hugo Dibarboure; Juan Guillermo Lopez
Journal:  Hum Vaccin Immunother       Date:  2022-03-28       Impact factor: 4.526

4.  Forecasting the Incremental Value to Society Created by a Class of New Prescription Drugs: A Proposed Methodology and Its Application to Treating Chronic Hepatitis C in India.

Authors:  V Srinivasan; David E Bloom; Alex Khoury
Journal:  Appl Health Econ Health Policy       Date:  2022-03-11       Impact factor: 3.686

Review 5.  The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review.

Authors:  Joseph Kazibwe; Adrian Gheorghe; David Wilson; Francis Ruiz; Kalipso Chalkidou; Y-Ling Chi
Journal:  Value Health       Date:  2021-10-29       Impact factor: 5.725

6.  The Cost-Effectiveness Analysis of the Productivity Measurement and Enhancement System Intervention to Reduce Employee Work-Related Stress and Enhance Work Performance.

Authors:  Irene Jensen; Zana Arapovic-Johansson; Emmanuel Aboagye
Journal:  Int J Environ Res Public Health       Date:  2022-02-19       Impact factor: 3.390

Review 7.  Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy.

Authors:  Chris Sampson; Bernarda Zamora; Sam Watson; John Cairns; Kalipso Chalkidou; Patricia Cubi-Molla; Nancy Devlin; Borja García-Lorenzo; Dyfrig A Hughes; Ashley A Leech; Adrian Towse
Journal:  Appl Health Econ Health Policy       Date:  2022-06-07       Impact factor: 3.686

8.  Cost-effectiveness of hypertension therapy based on 2020 International Society of Hypertension guidelines in Ethiopia from a societal perspective.

Authors:  Majid Davari; Mende Mensa Sorato; Abbas Kebriaeezadeh; Nizal Sarrafzadegan
Journal:  PLoS One       Date:  2022-08-29       Impact factor: 3.752

9.  Modelling the cost-effectiveness of essential and advanced critical care for COVID-19 patients in Kenya.

Authors:  Angela Kairu; Vincent Were; Lynda Isaaka; Ambrose Agweyu; Samuel Aketch; Edwine Barasa
Journal:  BMJ Glob Health       Date:  2021-12

10.  Cost-effectiveness of routine adolescent vaccination with an M72/AS01E-like tuberculosis vaccine in South Africa and India.

Authors:  Rebecca C Harris; Matthew Quaife; Chathika Weerasuriya; Gabriela B Gomez; Tom Sumner; Fiammetta Bozzani; Richard G White
Journal:  Nat Commun       Date:  2022-02-01       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.